Compare SUVEN LIFE with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES ASTRAZENECA PHARMA SUVEN LIFESCIENCES/
ASTRAZENECA PHARMA
 
P/E (TTM) x 21.1 96.2 22.0% View Chart
P/BV x 4.3 27.1 15.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUVEN LIFESCIENCES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
ASTRAZENECA PHARMA
Mar-18
SUVEN LIFESCIENCES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3381,278 26.4%   
Low Rs169883 19.2%   
Sales per share (Unadj.) Rs52.1228.4 22.8%  
Earnings per share (Unadj.) Rs6.810.4 65.9%  
Cash flow per share (Unadj.) Rs8.616.3 52.7%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.398.8 66.1%  
Shares outstanding (eoy) m127.2825.00 509.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.94.7 102.8%   
Avg P/E ratio x37.1104.2 35.6%  
P/CF ratio (eoy) x29.666.4 44.5%  
Price / Book Value ratio x3.910.9 35.5%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,27227,008 119.5%   
No. of employees `0001.11.4 79.8%   
Total wages/salary Rs m6611,535 43.1%   
Avg. sales/employee Rs Th6,132.24,210.9 145.6%   
Avg. wages/employee Rs Th611.11,132.2 54.0%   
Avg. net profit/employee Rs Th803.5191.1 420.5%   
INCOME DATA
Net Sales Rs m6,6355,710 116.2%  
Other income Rs m242123 197.8%   
Total revenues Rs m6,8775,833 117.9%   
Gross profit Rs m1,604463 346.6%  
Depreciation Rs m221147 150.2%   
Interest Rs m380-   
Profit before tax Rs m1,587438 362.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m718179 401.3%   
Profit after tax Rs m869259 335.5%  
Gross profit margin %24.28.1 298.2%  
Effective tax rate %45.240.8 110.7%   
Net profit margin %13.14.5 288.8%  
BALANCE SHEET DATA
Current assets Rs m6,2323,209 194.2%   
Current liabilities Rs m1,4902,070 72.0%   
Net working cap to sales %71.520.0 358.1%  
Current ratio x4.21.6 269.7%  
Inventory Days Days8672 119.5%  
Debtors Days Days8335 236.5%  
Net fixed assets Rs m4,043790 511.6%   
Share capital Rs m12750 254.6%   
"Free" reserves Rs m8,1832,419 338.2%   
Net worth Rs m8,3102,469 336.5%   
Long term debt Rs m180-   
Total assets Rs m10,3894,605 225.6%  
Interest coverage x43.1NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.61.2 51.5%   
Return on assets %8.75.6 155.2%  
Return on equity %10.510.5 99.7%  
Return on capital %19.517.7 110.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,622300 1,876.7%   
Fx outflow Rs m1,7992,015 89.3%   
Net fx Rs m3,822-1,715 -222.8%   
CASH FLOW
From Operations Rs m35688 404.4%  
From Investments Rs m-279-94 297.6%  
From Financial Activity Rs m-225NA-  
Net Cashflow Rs m-148-6 2,600.0%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 0.3 -  
FIIs % 0.0 15.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 9.1 401.1%  
Shareholders   37,287 12,856 290.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Nov 20, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS